[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Forte Biosciences Inc (FBRX)

Forte Biosciences Inc (FBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,066,722
  • Shares Outstanding, K 13,886
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,380 K
  • EBIT $ -77 M
  • EBITDA $ -77 M
  • 60-Month Beta 2.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 25.33

Options Overview Details

View History
  • Implied Volatility 10.44% (-0.01%)
  • Historical Volatility 198.67%
  • IV Percentile 3%
  • IV Rank 1.20%
  • IV High 291.19% on 11/06/25
  • IV Low 7.04% on 07/29/26
  • Expected Move (DTE 10) 0.00 (0.00%)
  • Put/Call Vol Ratio 63.33
  • Today's Volume 193
  • Volume Avg (30-Day) 538
  • Put/Call OI Ratio 2.88
  • Today's Open Interest 9,108
  • Open Int (30-Day) 4,790
  • Expected Range 76.87 to 76.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.08
  • Number of Estimates 1
  • High Estimate $-1.08
  • Low Estimate $-1.08
  • Prior Year $-0.96
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.11 +91.65%
on 07/13/26
77.20 -0.43%
on 07/30/26
+32.95 (+75.02%)
since 07/10/26
3-Month
15.51 +395.62%
on 06/08/26
77.20 -0.43%
on 07/30/26
+50.87 (+195.65%)
since 05/11/26
52-Week
9.91 +675.68%
on 08/14/25
77.20 -0.43%
on 07/30/26
+66.36 (+631.40%)
since 08/11/25

Most Recent Stories

More News
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Forte Biosciences ...

FBRX : 76.87 (+0.07%)
ARGX : 864.74 (-0.16%)
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

FBRX : 76.87 (+0.07%)
Are MKTX, SMTI, FBRX, LXFR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

FBRX : 76.87 (+0.07%)
MKTX : 162.53 (+0.02%)
SMTI : 34.38 (+0.38%)
LXFR : 17.08 (unch)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--FBRX, LXFR, SMTI, and MKTX

NEW YORK , Aug. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

FBRX : 76.87 (+0.07%)
MKTX : 162.53 (+0.02%)
SMTI : 34.38 (+0.38%)
LXFR : 17.08 (unch)
The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and...

FBRX : 76.87 (+0.07%)
ARGX : 864.74 (-0.16%)
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Forte Biosciences ...

FBRX : 76.87 (+0.07%)
ARGX : 864.74 (-0.16%)
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap

September Nasdaq 100 E-Mini futures (NQU26) are down -1.07% this morning as investors continued to ditch chipmakers amid concerns over the sustainability of the AI spending boom.

KLAC : 200.47 (+4.01%)
FBRX : 76.87 (+0.07%)
PHIA.NA : 23.550 (+1.03%)
SNDK : 1,271.05 (+2.68%)
KO : 86.48 (-0.45%)
NQU26 : 29,690.50 (+0.22%)
ASML.NA : 1,554.000 (+2.66%)
JNJ : 259.80 (-0.77%)
MU : 868.52 (+0.87%)
AAL : 15.29 (+1.93%)
WDAY : 181.27 (-1.59%)
GLW : 159.19 (+0.91%)
Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

FBRX : 76.87 (+0.07%)
BGMS : 0.9001 (+0.09%)
ACA : 144.91 (+0.12%)
Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical Tensions

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.32%. September E-mini...

ALK : 48.40 (+2.41%)
SNDK : 1,271.05 (+2.68%)
SLB : 53.68 (+0.90%)
TRI : 104.84 (+0.46%)
FDXF : 139.51 (-1.30%)
OXY : 59.06 (+0.70%)
FANG : 201.71 (+1.38%)
STX : 820.52 (+2.44%)
WDC : 437.93 (-0.09%)
AMD : 474.32 (+1.01%)
SPY : 770.56 (-0.32%)
FBRX : 76.87 (+0.07%)
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!

FBRX : 76.87 (+0.07%)
ARGX : 864.74 (-0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.

See More

Key Turning Points

3rd Resistance Point 76.98
2nd Resistance Point 76.94
1st Resistance Point 76.90
Last Price 76.87
1st Support Level 76.82
2nd Support Level 76.78
3rd Support Level 76.74

See More

52-Week High 77.20
Last Price 76.87
Fibonacci 61.8% 51.50
Fibonacci 50% 43.56
Fibonacci 38.2% 35.61
52-Week Low 9.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.